Share on StockTwits
 

Analysts at Jefferies Group raised their price objective on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $106.00 to $145.00 in a research report issued to clients and investors on Friday, ARN reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s price target suggests a potential downside of 8.65% from the company’s current price.

A number of other firms have also recently commented on ALXN. Analysts at Leerink Swann raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $200.00 in a research note to investors on Friday. Separately, analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $161.00 to $200.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Alexion Pharmaceuticals from $141.00 to $181.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $149.28.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.02% during mid-day trading on Friday, hitting $158.73. 3,063,832 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $169.98. The stock’s 50-day moving average is $134.5 and its 200-day moving average is $119.3. The company has a market cap of $31.123 billion and a price-to-earnings ratio of 91.63.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. On average, analysts predict that Alexion Pharmaceuticals will post $3.60 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP Stephen P. Squinto unloaded 1,118 shares of Alexion Pharmaceuticals stock on the open market in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $133.31, for a total value of $149,040.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.